Vertex Pharmaceuticals (NASDAQ:VRTX)

FDA_logo

Key FDA Decisions and Trial Results Coming in the Next 2 Months

U.S. Food and Drug Administration (FDA) rulings and the results from clinical trials have proven time and again that they can make or break companies. The biotech and pharmaceutical ...
Read Full Story »
FDA_logo

8 Major FDA Decisions and Trial Results to Watch for in September

Pharmaceutical and biotech companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount to a great amount ...
Read Full Story »
Pills and tablets

Biotechs With Drug Pipelines Closest to Zero Valuation

As biotech valuations and share price remain muted versus historic trends, investors have been evaluating which of the best biotech companies are offering the most upside. Other investors are looking ...
Read Full Story »
automatic inspection machine

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health ...
Read Full Story »
Female patient on gurney

5 Major Clinical Trial Results Coming Up

Pharmaceutical and biotech companies generally must endure the lengthy process that is getting their drug candidates to market through clinical trials. There is a fair amount to a great amount ...
Read Full Story »
Pills and tablets

How Analysts View Vertex After Earnings

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) reported its first-quarter financial results on Wednesday after the markets closed. Despite making some solid gains on Thursday after a mixed earnings report, the stock ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Facebook, First Solar, Hess, Texas Instruments, US Steel, Vertex, Infinera and More

Stocks were indicated to open handily lower on Thursday, after a disappointing no-change stance from the Bank of Japan caused stocks to slide globally. Despite the prices on Thursday, the ...
Read Full Story »
Test tubes

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

The flurry of earnings starts this week, and depending on who you listen to, the numbers are either going to be fine or they will be disappointing. One thing is ...
Read Full Story »
graph

3 Hot Growth Stocks With Upside Potential That May Not Be Appreciated by Wall Street

Sometimes after a stock has a good run, the analysts on Wall Street start to get a little gun-shy, especially if they made a good call on the stock and ...
Read Full Story »
graph

5 Biotechs With the Most Upside This Earnings Cycle

With earnings just around the corner, one key analyst is taking the opportunity to share its thoughts on select mid-cap and large-cap biotech companies. Despite a modest erosion to fundamentals and sector ...
Read Full Story »
biotech word cloud

8 Major Biopharma Events Coming Later in 2016 and in 2017

Companies in the pharmaceutical industry generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There can be a fair amount of risk ...
Read Full Story »
automatic inspection machine

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

Biotech stocks have been absolutely beaten up over the past eight months, even the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) is down over 20% year to date. However this could ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Chipotle, Cisco, Micron, Seagate, Vertex, Disney, Xerox and Many More

Stocks were indicated handily lower on Monday. Investors have seen so far in 2016 that rallies have been sold off, but for over four years, before January, every single market ...
Read Full Story »
FDA_logo

3 Key FDA Decisions Expected in February

Companies in the pharmaceutical industry are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, ...
Read Full Story »
biotech word cloud

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. There is a challenging macro setup, but headwinds combined with a relatively attractive valuation could carry ...
Read Full Story »